Bayer and Algeta's Alpharadin efficacy confirmed; Almirall to market Xarelto in Spain

13 February 2012

German drug major Bayer (BAY: DE) and Norwegian partner Algeta (OSE: ALGETA) announced that the survival analysis has been completed on updated clinical data generated from the ALSYMPCA Phase III trial evaluating Alpharadin(radium-223 chloride) in patients with castration-resistant prostate cancer (CRPC) and bone metastases.

The updated analysis confirmed the overall efficacy results of the pre-planned interim analysis from June 2011, showing an increase in median overall survival of 3.6 months (14.9 months in the Alpharadin arm versus 11.3 months in the placebo arm). The hazard ratio was unchanged and the p-value improved.

Regulatory submissions anticipated mid-2012

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK